Do analysts rate IZTC or KPRX?

Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 299.20%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kiora Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, IZTC or KPRX?

Invizyne Technologies has higher earnings, but lower revenue than Kiora Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Kiora Pharmaceuticals $16.02M 0.69 -$10.84M -$2.71 N/A

Is IZTC or KPRX more profitable?

Invizyne Technologies' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A Kiora Pharmaceuticals N/A -59.30% -41.23%

Is KPRX or PDSB more profitable?

Kiora Pharmaceuticals' return on equity of -59.30% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -59.30% -41.23% PDS Biotechnology N/A -346.02% -102.36%

Is KPRX or ACTU more profitable?

Kiora Pharmaceuticals' return on equity of -59.30% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -59.30% -41.23% Actuate Therapeutics N/A -430.93% -180.86%

Is GRCE or KPRX more profitable?

Grace Therapeutics' return on equity of -14.45% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -14.45% -13.58% Kiora Pharmaceuticals N/A -59.30% -41.23%

Kiora Pharmaceuticals (KPRX) Competitors

$2.50 -0.05 (-1.76%)

Closing price 07/27/2026 03:59 PM Eastern

Extended Trading

$2.52 +0.02 (+0.80%)

As of 07/27/2026 04:10 PM Eastern

Compare

KPRX vs. IZTC, PDSB, CRVO, ACTU, and GRCE

Should you buy Kiora Pharmaceuticals stock or one of its competitors? MarketBeat compares Kiora Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kiora Pharmaceuticals include Invizyne Technologies (IZTC), PDS Biotechnology (PDSB), CervoMed (CRVO), Actuate Therapeutics (ACTU), and Grace Therapeutics (GRCE). These companies are all part of the "pharmaceutical products" industry.

How does Kiora Pharmaceuticals compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Kiora Pharmaceuticals and 0 mentions for Invizyne Technologies. Kiora Pharmaceuticals' average media sentiment score of 1.87 beat Invizyne Technologies' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Kiora Pharmaceuticals	Very Positive

Invizyne Technologies has higher earnings, but lower revenue than Kiora Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Kiora Pharmaceuticals	$16.02M	0.69	-$10.84M	-$2.71	N/A

Invizyne Technologies' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 299.20%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Kiora Pharmaceuticals beats Invizyne Technologies on 8 of the 10 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to PDS Biotechnology?

Kiora Pharmaceuticals (NASDAQ:KPRX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Kiora Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 299.20%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 1,199.26%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Kiora Pharmaceuticals has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.69	-$10.84M	-$2.71	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

Kiora Pharmaceuticals' return on equity of -59.30% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
PDS Biotechnology	N/A	-346.02%	-102.36%

Kiora Pharmaceuticals has a beta of -0.4, meaning that its share price is 140% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, PDS Biotechnology had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 2 mentions for PDS Biotechnology and 1 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.87 beat PDS Biotechnology's score of 0.77 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Very Positive
PDS Biotechnology	Positive

Summary

Kiora Pharmaceuticals and PDS Biotechnology tied by winning 7 of the 14 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to CervoMed?

Kiora Pharmaceuticals (NASDAQ:KPRX) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Kiora Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Kiora Pharmaceuticals' return on equity of -59.30% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
CervoMed	-672.80%	-136.08%	-112.62%

Kiora Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 299.20%. CervoMed has a consensus target price of $22.60, suggesting a potential upside of 749.62%. Given CervoMed's stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, CervoMed had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 2 mentions for CervoMed and 1 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.87 beat CervoMed's score of 0.94 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Very Positive
CervoMed	Positive

Kiora Pharmaceuticals has higher revenue and earnings than CervoMed. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.69	-$10.84M	-$2.71	N/A
CervoMed	$4.01M	8.98	-$26.97M	-$3.28	N/A

Kiora Pharmaceuticals has a beta of -0.4, indicating that its share price is 140% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.68, indicating that its share price is 168% less volatile than the broader market.

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 35.8% of CervoMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Kiora Pharmaceuticals beats CervoMed on 9 of the 16 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Actuate Therapeutics?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

In the previous week, Kiora Pharmaceuticals and Kiora Pharmaceuticals both had 1 articles in the media. Actuate Therapeutics' average media sentiment score of 1.89 beat Kiora Pharmaceuticals' score of 1.87 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Very Positive
Actuate Therapeutics	Very Positive

Kiora Pharmaceuticals has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.69	-$10.84M	-$2.71	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Kiora Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 299.20%. Actuate Therapeutics has a consensus price target of $17.50, indicating a potential upside of 1,421.74%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kiora Pharmaceuticals' return on equity of -59.30% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
Actuate Therapeutics	N/A	-430.93%	-180.86%

Kiora Pharmaceuticals has a beta of -0.4, meaning that its share price is 140% less volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Summary

Actuate Therapeutics beats Kiora Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Grace Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 160.87%. Kiora Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 299.20%. Given Kiora Pharmaceuticals' higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Grace Therapeutics had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 2 mentions for Grace Therapeutics and 1 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.87 beat Grace Therapeutics' score of 0.95 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Grace Therapeutics	Positive
Kiora Pharmaceuticals	Very Positive

Grace Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.4, suggesting that its share price is 140% less volatile than the broader market.

Grace Therapeutics has higher earnings, but lower revenue than Kiora Pharmaceuticals. Grace Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A
Kiora Pharmaceuticals	$16.02M	0.69	-$10.84M	-$2.71	N/A

Grace Therapeutics' return on equity of -14.45% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-14.45%	-13.58%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Grace Therapeutics beats Kiora Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Kiora Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPRX vs. The Competition

Export

Metric	Kiora Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.30M	$3.08B	$6.90B	$12.17B
Dividend Yield	N/A	2.08%	2.67%	9.42%
P/E Ratio	-0.92	20.21	27.03	23.74
Price / Sales	0.69	379.45	495.42	79.01
Price / Cash	N/A	26.63	26.39	46.67
Price / Book	0.57	4.35	10.36	6.16
Net Income	-$10.84M	$65.94M	$3.60B	$331.26M
7 Day Performance	-0.99%	-2.89%	-1.64%	-0.71%
1 Month Performance	-1.38%	-4.86%	-2.57%	-2.52%
1 Year Performance	-14.51%	11.52%	18.63%	14.76%

Kiora Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPRX Kiora Pharmaceuticals	2.4239 of 5 stars	$2.51 -1.8%	$10.00 +299.2%	-16.2%	$11.30M	$16.02M	N/A	10	Positive News
IZTC Invizyne Technologies	N/A	$7.00 +9.9%	N/A	-52.8%	$43.76M	N/A	N/A	29	Gap Up
PDSB PDS Biotechnology	2.0517 of 5 stars	$0.75 -0.8%	$9.00 +1,106.4%	-41.3%	$42.05M	N/A	N/A	20	Analyst Downgrade
CRVO CervoMed	3.2278 of 5 stars	$3.07 -0.3%	$22.60 +636.2%	-70.4%	$41.66M	$4.01M	N/A	4	Gap Up
ACTU Actuate Therapeutics	2.8559 of 5 stars	$1.72 -0.6%	$17.50 +917.4%	-84.2%	$41.39M	N/A	N/A	10	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPRX) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. IZTC, PDSB, CRVO, ACTU, and GRCE

How does Kiora Pharmaceuticals compare to Invizyne Technologies?

Summary

How does Kiora Pharmaceuticals compare to PDS Biotechnology?

Summary

How does Kiora Pharmaceuticals compare to CervoMed?

Summary

How does Kiora Pharmaceuticals compare to Actuate Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to Grace Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. IZTC, PDSB, CRVO, ACTU, and GRCE

How does Kiora Pharmaceuticals compare to Invizyne Technologies?

Does the media prefer IZTC or KPRX?

Which has stronger valuation & earnings, IZTC or KPRX?

Is IZTC or KPRX more profitable?

Do analysts rate IZTC or KPRX?

Do institutionals and insiders hold more shares of IZTC or KPRX?

Summary

How does Kiora Pharmaceuticals compare to PDS Biotechnology?

Do analysts rate KPRX or PDSB?

Which has preferable earnings & valuation, KPRX or PDSB?

Is KPRX or PDSB more profitable?

Which has more risk and volatility, KPRX or PDSB?

Do insiders & institutionals hold more shares of KPRX or PDSB?

Does the media prefer KPRX or PDSB?

Summary

How does Kiora Pharmaceuticals compare to CervoMed?

Is KPRX or CRVO more profitable?

Do analysts rate KPRX or CRVO?

Does the media prefer KPRX or CRVO?

Which has stronger valuation & earnings, KPRX or CRVO?

Which has more volatility and risk, KPRX or CRVO?

Do insiders and institutionals hold more shares of KPRX or CRVO?

Summary

How does Kiora Pharmaceuticals compare to Actuate Therapeutics?

Does the media favor KPRX or ACTU?

Which has higher earnings & valuation, KPRX or ACTU?

Do analysts prefer KPRX or ACTU?

Do institutionals & insiders hold more shares of KPRX or ACTU?

Is KPRX or ACTU more profitable?

Which has more volatility and risk, KPRX or ACTU?

Summary

How does Kiora Pharmaceuticals compare to Grace Therapeutics?

Do analysts recommend GRCE or KPRX?

Does the media refer more to GRCE or KPRX?

Which has more risk and volatility, GRCE or KPRX?

Which has stronger earnings & valuation, GRCE or KPRX?

Is GRCE or KPRX more profitable?

Do institutionals and insiders believe in GRCE or KPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools